Orthocell Rockets to Record $2.21M Revenue, Eyes US FDA Approval for Remplir™

• Record quarterly revenue of $2.21 million, up 9% sequentially and 46% year-over-year
• Received regulatory approval and achieved first sales of Remplir™ in Singapore
• Submitted US FDA 510(k) application for Remplir™, targeting $1.6 billion US nerve repair market
• Completed $17 million capital raise to fund US commercial launch and global expansion